Amy V. Kapp

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Mark R. Middleton, Jean‐Jacques Grob, Neil K. Aaronson et al. · Journal of Clinical Oncology · 2000 · 1.3K citations

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 463 citations · Full text

First-line Therapy, Breast Oncology, Medicine +7

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Delvys Rodríguez‐Abreu, Melissa L. Johnson, Maen Hussein et al. · Journal of Clinical Oncology · 2020 · 240 citations

Pd-l1-selected Nsclc, Immunology, Immunoediting +20

Are clusters found in one dataset present in another dataset?

Amy V. Kapp, Robert Tibshirani · Biostatistics · 2006 · 190 citations

Engineering, Independent Dataset, Unsupervised Machine Learning +17

Discovery and validation of breast cancer subtypes

Amy V. Kapp, Stefanie S. Jeffrey, Anita Langerød et al. · BMC Genomics · 2006 · 129 citations · Full text